WASHINGTON - The American Pharmaceutical Association awarded Mount Olive, NJ-based Knoll Pharmaceutical Co. the 15th annual H.A.B. Dunning Award.
WASHINGTON - The American Pharmaceutical Association awarded Mount Olive, NJ-based Knoll Pharmaceutical Co. the 15th annual H.A.B. Dunning Award.
The award, which recognizes exemplary contributions to the practice of pharmacy by a pharmaceutical manufacturer or provider of support products and services, will be presented during the association's 145th annual meeting and exposition in Miami Beach, FL, in March.
Knoll was nominated by the Texas Pharmacy Association for its support of educational consumer awareness and independent business programs. The association also benefited from Knoll's funding of expanded educational facilities, which allowed the association to increase its capacity by one-third. In addition, Knoll sponsored a family night for pharmacists and their families to encourage networking; an appreciation banquet for pharmacists; and a county art auction that benefited the surrounding communities.
"In each contribution, Knoll's people are with us every step of the way - evaluating the programs, looking for ways to make them better and encouraging other organizations to support our pharmacists," wrote Luther Parker, association president, and Paul Davis, association executive director, in explanation of the nomination. "We believe Knoll deserves this award not only because of the numerous contributions the company made in 1997, but also because of Knoll's history of support, and its future commitment to the practice of pharmacy." PR
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.